Form 4: Cullinan CFO Sells Shares for Tax Obligations

Cullinan Therapeutics' CFO, Mary Kay Fenton, sold 4,398 shares of common stock at $13.62 per share to cover tax obligations related to vested restricted stock units.

Summary

• Mary Kay Fenton, Chief Financial Officer of Cullinan Therapeutics, Inc. (CGEM), reported a transaction.
• On February 20, 2026, Fenton sold 4,398 shares of Cullinan Therapeutics Common Stock.
• The shares were sold at a price of $13.62 per share.
• The purpose of the sale was to cover personal income tax obligations arising from the vesting of restricted stock units.
• Following this transaction, Fenton beneficially owns 126,380 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a standard practice for tax purposes related to RSU vesting and does not indicate a change in the executive's confidence or the company's fundamentals.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that sales by executives to cover tax obligations upon the vesting of restricted stock units (RSUs) are a common and routine occurrence across all industries, particularly in high-growth sectors like biotechnology, where equity compensation is prevalent. These sales are generally not interpreted as a lack of confidence in the company's future prospects but rather as a necessary action to manage personal tax liabilities.

Comparison to Industry Standards

• This type of transaction is standard practice for executives receiving equity compensation. For example, executives at companies like Moderna (MRNA) or Pfizer (PFE) frequently execute similar "sell-to-cover" transactions when their restricted stock units vest, aligning with common compensation structures in the pharmaceutical and biotech industries.

Related Party Transactions

• The transaction involves the Chief Financial Officer, Mary Kay Fenton, selling shares to cover personal income tax obligations related to vested restricted stock units, which is a routine compensation-related transaction for an insider.

Stakeholder Impact

• Shareholders: Minimal direct impact. A small reduction in insider ownership, but for a non-discretionary reason.
• Employees: No direct impact.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Key Dates

Recommendation

The reported transaction is a routine 'sell-to-cover' sale by the CFO to satisfy tax obligations upon the vesting of restricted stock units. This is a common practice and does not typically signal a change in the company's fundamental outlook or the executive's confidence. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Cullinan Therapeutics, CGEM, Form 4, Insider Trading, Stock Sale, CFO, Restricted Stock Units, Tax Obligations, Executive Compensation